Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 23 of 100 as at 8 Oct 2026 — in the weakest quartile.
Consensus tells you what everyone already believes. The model scores VERAXA Biotech AG on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Size (70): Smaller than most of the companies we track.
Momentum (19): The shares have been drifting down relative to others.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on VRXA, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. VRXA appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 9 Oct 2026, VERAXA Biotech AG returned −88.3% against +17.3% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 1% of US stocks
Cheaper than 84% of US stocks
Cheaper than 75% of US stocks
Higher than 1% of US stocks
Higher than 98% of US stocks
Higher than 2% of US stocks
Higher than 8% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
VERAXA Biotech AG has a market value of $169.7M and an enterprise value of $170.2M.
Forward dividend yield: 0.00%, paying out 0% of earnings.
VERAXA Biotech AG employs 0 people.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own VERAXA Biotech AG — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Veraxa Biotech is shifting away from animal testing, describing the change as both a regulatory obligation and a scientific opportunity to get drugs to market faster. The headline notes that the micro-cap stock is down 96% this year.
Why it matters — VRXA watchers may care about the company’s approach to drug testing and its stated aim of speeding drug development.
VERAXA Biotech outlined plans to implement FDA-aligned human-relevant models, or New Approach Methodologies, in its R&D strategy. The company said consistent use of these methods could potentially accelerate its BiTAC® oncology pipeline and significantly reduce animal testing needs.
Why it matters — The update describes a change in VERAXA’s research approach that may affect pipeline development and reliance on animal testing.
VERAXA Biotech AG announced the appointment of Raju Willener as Chief Financial Officer, effective immediately. Willener joins the antibody-based cancer therapy developer based in Zurich, Switzerland.
Why it matters — A new CFO brings a change in financial leadership that VRXA watchers will want to track for future financial management and reporting.
VERAXA Biotech announced that during the first half of 2026 it filed initial patent applications covering its new BiTAC-TCE and BiTAC-ADC platforms and related therapeutic programs.
Why it matters — Patent filings help protect VERAXA's core technology platforms and product candidates, which could strengthen the company's competitive position as it develops novel cancer therapies.
VERAXA Biotech's bispecific antibody drug conjugate program VXA-222, developed through a joint discovery collaboration with OmniAb, is advancing into the next phase after a key technical milestone was achieved.
Why it matters — The progression of VXA-222 into the next development phase signals continued pipeline advancement for VERAXA Biotech.
As at 8 Oct 2026, VERAXA Biotech AG ranks 23 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (70 of 100).
No analyst covering VERAXA Biotech AG publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for VRXA are extrapolating price history, which says nothing about the business.
VERAXA Biotech AG returned -88.3% over the 12 months to 9 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
Veraxa Biotech AG is a clinical-stage biotechnology company focused on the discovery and development of novel antibody-based cancer therapies. The company works on antibody-drug conjugates and bispecific antibody formats, using proprietary screening and bioconjugation technologies to create targeted oncology candidates.
The most recent item we track (Barrons, 7 Oct 2026): "Micro-Cap Stock Veraxa Biotech Is Down 96% This Year. Can Next-Gen Drug Testing Save It?". Veraxa Biotech is shifting away from animal testing, describing the change as both a regulatory obligation and a scientific opportunity to get drugs to market faster. The headline notes that the micro-cap stock is down 96% this year.
Veraxa Biotech AG is a clinical-stage biotechnology company focused on the discovery and development of novel antibody-based cancer therapies. The company works on antibody-drug conjugates and bispecific antibody formats, using proprietary screening and bioconjugation technologies to create targeted oncology candidates. Its current pipeline centers on drug programs in acute myeloid leukemia and other cancer indications, reflecting a focus on precise, mechanism-driven treatment approaches. Veraxa Biotech AG also develops platform capabilities intended to support the identification, engineering, and optimization of therapeutic antibodies for internal programs and collaborative partnerships. Based in Zurich, Switzerland, with research and development operations in Heidelberg, Germany, the company operates within the oncology biotechnology market and contributes to the broader advancement of next-generation biologic medicines.
CEO Dr. Christoph Antz Ph.D. · Germany · https://www.veraxa.com
